P
Paul Barragan
Researcher at Erasmus University Rotterdam
Publications - 74
Citations - 9646
Paul Barragan is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Stent & Percutaneous coronary intervention. The author has an hindex of 28, co-authored 72 publications receiving 9285 citations. Previous affiliations of Paul Barragan include French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary Revascularization
Marie-Claude Morice,Patrick W. Serruys,J. Eduardo Sousa,Jean Fajadet,Ernesto Ban Hayashi,Marco Antonio Perin,Antonio Colombo,Gerhard Schuler,Paul Barragan,Giulio Guagliumi,Ferenc Molnar,Robert Falotico +11 more
TL;DR: As compared with a standard coronary stent, a sirolimus-eluting stent shows considerable promise for the prevention of neointimal proliferation, restenosis, and associated clinical events.
Journal ArticleDOI
Platelet Glycoprotein IIb/IIIa Inhibition with Coronary Stenting for Acute Myocardial Infarction
Gilles Montalescot,Paul Barragan,Olivier Wittenberg,Patrick Ecollan,Simon Elhadad,Philippe Villain,Jean-Marc Boulenc,Marie-Claude Morice,Luc Maillard,Michel Pansieri,Rémi Choussat,P. Pinton +11 more
TL;DR: Early administration of abciximab in patients with acute myocardial infarction improves coronary patency before stenting, the success rate of the stenting procedure, the rate of coronaryPatency at six months, left ventricular function, and clinical outcomes.
Journal ArticleDOI
Adjusted Clopidogrel Loading Doses According to Vasodilator-Stimulated Phosphoprotein Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance A Multicenter Randomized Prospective Study
Laurent Bonello,Laurence Camoin-Jau,Stephane Arques,Christian Boyer,Dimitri Panagides,Olivier Wittenberg,Marie Claude Simeoni,Paul Barragan,Françoise Dignat-George,Franck Paganelli +9 more
TL;DR: This is the first study to suggest that adjusting the clopidogrel loading dose according to platelet monitoring using the VASP index is safe and may significantly improve the clinical outcome after PCI in patients with clopinogrel resistance despite a first 600-mg loading dose.
Journal ArticleDOI
Cyclosporine before PCI in Patients with Acute Myocardial Infarction
Thien-Tri Cung,Olivier Morel,Guillaume Cayla,Gilles Rioufol,David Garcia-Dorado,Denis Angoulvant,Eric Bonnefoy-Cudraz,Patrice Guerin,Meier Elbaz,Nicolas Delarche,Pierre Coste,Gérald Vanzetto,Marc Metge,Jean-François Aupetit,Bernard Jouve,Pascal Motreff,Christophe Tron,Jean-Noël Labèque,Philippe Gabriel Steg,Yves Cottin,Grégoire Rangé,Jérôme Clerc,Marc J. Claeys,P Coussement,Fabrice Prunier,Frédéric Moulin,Olivier Roth,Loic Belle,Philippe Dubois,Paul Barragan,Martine Gilard,Christophe Piot,Patrice Colin,Fabien de Poli,Marie-Claude Morice,Omar Ider,Jean-Luc Dubois-Randé,Thierry Unterseeh,Hervé Le Breton,Thierry Beard,Didier Blanchard,Gilles Grollier,Vincent Malquarti,P. Staat,Arnaud Sudre,Eskil Elmér,Magnus Hansson,Cyrille Bergerot,Inesse Boussaha,Claire Jossan,Geneviève Derumeaux,Nathan Mewton,Michel Ovize +52 more
TL;DR: In patients with anterior STEMI who had been referred for primary PCI, intravenous cyclosporine did not result in better clinical outcomes than those with placebo and did not prevent adverse left ventricular remodeling at 1 year.
Journal ArticleDOI
6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial.
Martine Gilard,Paul Barragan,Arif A.L. Noryani,Hussam A. Noor,Talib Majwal,Thomas Hovasse,Philippe Castellant,Michel Schneeberger,Luc Maillard,Erwan Bressolette,Jarosław Wójcik,Nicolas Delarche,Didier Blanchard,Bernard Jouve,O. Ormezzano,Franck Paganelli,Gilles Levy,Joel Sainsous,Didier Carrié,Alain Furber,Jacques Berland,Oliver Darremont,Hervé Le Breton,Anne Lyuycx-Bore,Antoine Gommeaux,Claude Cassat,Alain Kermarrec,Pierre Cazaux,Philippe Druelles,Raphael Dauphin,Jean Armengaud,Patrick Dupouy,Didier Champagnac,Patrick Ohlmann,Knut Endresen,Hakim Benamer,Róbert Gábor Kiss,Imre Ungi,Jacques Boschat,Marie-Claude Morice +39 more
TL;DR: Rates of bleeding and thrombotic events were not significantly different according to 6- versus 24-month DAPT after PCI with new-generation DES in good aspirin responders in aspirin-sensitive patients.